LIQ 001

Drug Profile

LIQ 001

Alternative Names: LIQ001

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator Liquidia Technologies
  • Class Influenza virus vaccines; Pancreatic enzymes; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza virus infections

Most Recent Events

  • 14 Dec 2015 Phase I/II development is ongoing in USA
  • 01 Dec 2011 Liquidia Technologies completes its phase I/II trial for Influenza virus infections (Prevention, In adult and elderly volunteers) in USA (NCT01224262)
  • 03 Jan 2011 Liquidia Technologies completes enrolment in its phase I/II trial for Influenza virus infections (Prevention, In adult and elderly volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top